Related Experiment Videos
Stakeholders' perspectives on quality indicators for diabetes care: a qualitative study
Joekie Markhorst1, Liana Martirosyan, Hiske Calsbeek
1IQ Scientific Institute for Quality of Healthcare (IQ healthcare), The Netherlands.
Quality in Primary Care
|November 2, 2012
Summary
Stakeholders in diabetes care have varied preferences for quality indicators. Prioritizing patient-centeredness and process measures can improve the selection and implementation of quality indicators.
Area of Science:
- Healthcare Quality Improvement
- Health Services Research
- Diabetes Care Management
Background:
- Transparency in diabetes care necessitates quality indicators aligned with stakeholder interests for optimal utilization.
- Current indicator development often relies on consensus, with limited understanding of stakeholder preferences for quality information.
Purpose of the Study:
- To investigate the preferences of consumers, providers, purchasers, and policymakers regarding quality domains and indicators in diabetes care.
- To understand how these preferences relate to the intended use of quality indicators.
Main Methods:
- Conducted 14 semi-structured interviews with key stakeholders involved in selecting the national diabetes care indicator set in the Netherlands (June-December 2009).
- Explored stakeholder aims for using quality information, their interpretation and preferences for quality domains (safety, timeliness, effectiveness, patient-centeredness, efficiency), and preferred indicator types (structure, process, outcome).
- Utilized content analysis to interpret qualitative data.
Main Results:
- Stakeholders exhibited both shared and distinct aims based on their roles, with significant variation in interpreting quality domains.
- Patient-centeredness was the highest priority across most stakeholders, followed by safety, effectiveness, and timeliness. Purchasers additionally prioritized efficiency.
- A preference for process indicators or a combination of process and outcome indicators was common among all stakeholders.
Conclusions:
- Stakeholder preferences for quality indicators in diabetes care appear unrefined and lack congruence.
- Enhancing the selection process by clarifying stakeholder definitions and preferences for quality domains can likely improve the implementation of indicator sets.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:25Errors occurring during blood pressure monitoring
Blood pressure monitoring is a crucial clinical procedure in diagnosing and managing various cardiovascular conditions. Despite its significance, the accuracy of blood pressure measurements can be compromised by multiple factors, potentially leading to either falsely high or low readings. These inaccuracies are critical as they can significantly impact patient care. So, it is vital to understand these challenges deeply and adopt strategic approaches to minimize errors.
Several factors...
Several factors...
01:26Diabetes Mellitus: Introduction
Diabetes mellitus consists of chronic metabolic disorders characterized by persistent hyperglycemia. This elevated blood glucose results from defects in insulin secretion, impaired insulin action, or both. Insulin, produced by pancreatic β-cells, is essential for maintaining glucose homeostasis by facilitating cellular glucose uptake for energy or storage. Disruptions in insulin production or function lead to glucose accumulation in the bloodstream, causing the clinical features and long-term...
01:15Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
01:22Diabetes Mellitus: Overview and Type I Subtype
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...